Nanoparticle-based drug delivery for chronic obstructive pulmonary disorder and asthma

Ridhima Wadhwa; Taru Aggarwal; Noopur Thapliyal; Dinesh Kumar Chellappan; Gaurav Gupta; Monica Gulati; Trudi Collet; Brian Oliver; Kylie Williams; Philip Michael Hansbro; Kamal Dua; Pawan Kumar Maurya

doi:10.1016/B978-0-12-818823-1.00005-3

Nanoparticle-based drug delivery for chronic obstructive pulmonary disorder and asthma

Ridhima Wadhwa
, Taru Aggarwal
, Noopur Thapliyal
, Dinesh Kumar Chellappan
, Gaurav Gupta
, Monica Gulati
, Trudi Collet
, Brian Oliver
, Kylie Williams
, Philip Michael Hansbro
, Kamal Dua
, Pawan Kumar Maurya

South Asian University
Amity University, Noida
International Medical University
University of Allahabad
Universidade Estadual de Campinas
Queensland University of Technology
University of Technology Sydney
Centre for InflammationCentenary Institute
Hunter Medical Research Institute, Australia
Central University of Haryana

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

27 Scopus citations

Abstract

Pulmonary diseases including chronic obstructive pulmonary disease (COPD) and asthma affect millions of people all over the world. Conventional treatment methodologies are not sufficient to cure or prevent the disease. With the advent of nanotechnology, drug delivery to specific target site is still challenging, but targeted delivery can be achieved by physiochemical properties of the nanoparticles. Delivery of nanoparticles, liposomes, dendrimers, and others has been extensively studied for successful delivery by inhalation and aerosols. Several factors such as size, density, surface, and physical-chemical properties of nanoparticle are essential to cross airway barriers. In this chapter, different nanoparticle-mediated drug delivery systems have been highlighted along with their applications and toxicity in COPD and asthma.

Original language	English
Title of host publication	Nanotechnology in Modern Animal Biotechnology
Subtitle of host publication	Concepts and Applications
Publisher	Elsevier
Pages	59-73
Number of pages	15
ISBN (Electronic)	9780128188231
DOIs	https://doi.org/10.1016/B978-0-12-818823-1.00005-3
State	Published - 1 Jan 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Asthma
Chronic obstructive pulmonary disease
Nanoparticles
Therapeutics
Toxicity

Access to Document

10.1016/B978-0-12-818823-1.00005-3

Cite this

Wadhwa, R., Aggarwal, T., Thapliyal, N., Chellappan, D. K., Gupta, G., Gulati, M., Collet, T., Oliver, B., Williams, K., Hansbro, P. M., Dua, K., & Maurya, P. K. (2019). Nanoparticle-based drug delivery for chronic obstructive pulmonary disorder and asthma. In Nanotechnology in Modern Animal Biotechnology: Concepts and Applications (pp. 59-73). Elsevier. https://doi.org/10.1016/B978-0-12-818823-1.00005-3

@inbook{5f76404da88541afa67f68fff4cffa61,

title = "Nanoparticle-based drug delivery for chronic obstructive pulmonary disorder and asthma",

abstract = "Pulmonary diseases including chronic obstructive pulmonary disease (COPD) and asthma affect millions of people all over the world. Conventional treatment methodologies are not sufficient to cure or prevent the disease. With the advent of nanotechnology, drug delivery to specific target site is still challenging, but targeted delivery can be achieved by physiochemical properties of the nanoparticles. Delivery of nanoparticles, liposomes, dendrimers, and others has been extensively studied for successful delivery by inhalation and aerosols. Several factors such as size, density, surface, and physical-chemical properties of nanoparticle are essential to cross airway barriers. In this chapter, different nanoparticle-mediated drug delivery systems have been highlighted along with their applications and toxicity in COPD and asthma.",

keywords = "Asthma, Chronic obstructive pulmonary disease, Nanoparticles, Therapeutics, Toxicity",

author = "Ridhima Wadhwa and Taru Aggarwal and Noopur Thapliyal and Chellappan, \{Dinesh Kumar\} and Gaurav Gupta and Monica Gulati and Trudi Collet and Brian Oliver and Kylie Williams and Hansbro, \{Philip Michael\} and Kamal Dua and Maurya, \{Pawan Kumar\}",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-818823-1.00005-3",

language = "English",

pages = "59--73",

booktitle = "Nanotechnology in Modern Animal Biotechnology",

publisher = "Elsevier",

address = "Netherlands",

}

Wadhwa, R, Aggarwal, T, Thapliyal, N, Chellappan, DK, Gupta, G, Gulati, M, Collet, T, Oliver, B, Williams, K, Hansbro, PM, Dua, K & Maurya, PK 2019, Nanoparticle-based drug delivery for chronic obstructive pulmonary disorder and asthma. in Nanotechnology in Modern Animal Biotechnology: Concepts and Applications. Elsevier, pp. 59-73. https://doi.org/10.1016/B978-0-12-818823-1.00005-3

TY - CHAP

T1 - Nanoparticle-based drug delivery for chronic obstructive pulmonary disorder and asthma

AU - Wadhwa, Ridhima

AU - Aggarwal, Taru

AU - Thapliyal, Noopur

AU - Chellappan, Dinesh Kumar

AU - Gupta, Gaurav

AU - Gulati, Monica

AU - Collet, Trudi

AU - Oliver, Brian

AU - Williams, Kylie

AU - Hansbro, Philip Michael

AU - Dua, Kamal

AU - Maurya, Pawan Kumar

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pulmonary diseases including chronic obstructive pulmonary disease (COPD) and asthma affect millions of people all over the world. Conventional treatment methodologies are not sufficient to cure or prevent the disease. With the advent of nanotechnology, drug delivery to specific target site is still challenging, but targeted delivery can be achieved by physiochemical properties of the nanoparticles. Delivery of nanoparticles, liposomes, dendrimers, and others has been extensively studied for successful delivery by inhalation and aerosols. Several factors such as size, density, surface, and physical-chemical properties of nanoparticle are essential to cross airway barriers. In this chapter, different nanoparticle-mediated drug delivery systems have been highlighted along with their applications and toxicity in COPD and asthma.

AB - Pulmonary diseases including chronic obstructive pulmonary disease (COPD) and asthma affect millions of people all over the world. Conventional treatment methodologies are not sufficient to cure or prevent the disease. With the advent of nanotechnology, drug delivery to specific target site is still challenging, but targeted delivery can be achieved by physiochemical properties of the nanoparticles. Delivery of nanoparticles, liposomes, dendrimers, and others has been extensively studied for successful delivery by inhalation and aerosols. Several factors such as size, density, surface, and physical-chemical properties of nanoparticle are essential to cross airway barriers. In this chapter, different nanoparticle-mediated drug delivery systems have been highlighted along with their applications and toxicity in COPD and asthma.

KW - Asthma

KW - Chronic obstructive pulmonary disease

KW - Nanoparticles

KW - Therapeutics

KW - Toxicity

UR - https://www.scopus.com/pages/publications/85081606434

U2 - 10.1016/B978-0-12-818823-1.00005-3

DO - 10.1016/B978-0-12-818823-1.00005-3

M3 - Chapter

AN - SCOPUS:85081606434

SP - 59

EP - 73

BT - Nanotechnology in Modern Animal Biotechnology

PB - Elsevier

ER -

Nanoparticle-based drug delivery for chronic obstructive pulmonary disorder and asthma

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this